Korean clinical practice guideline for benign prostatic hyperplasia

Investig Clin Urol. 2016 Jan;57(1):30-44. doi: 10.4111/icu.2016.57.1.30. Epub 2016 Jan 11.

Abstract

In 2014, the Korean Urological Association organized the Benign Prostatic Hyperplasia Guideline Developing Committee composed of experts in the field of benign prostatic hyperplasia (BPH) with the participation of the Korean Academy of Family Medicine and the Korean Continence Society to develop a Korean clinical practice guideline for BPH. The purpose of this clinical practice guideline is to provide current and comprehensive recommendations for the evaluation and treatment of BPH. The committee developed the guideline mainly by adapting existing guidelines and partially by using the de novo method. A comprehensive literature review was carried out primarily from 2009 to 2013 by using medical search engines including data from Korea. Based on the published evidence, recommendations were synthesized, and the level of evidence of the recommendations was determined by using methods adapted from the 2011 Oxford Centre for Evidence-Based Medicine. Meta-analysis was done for one key question and four recommendations. A draft guideline was reviewed by expert peer reviewers and discussed at an expert consensus meeting until final agreement was achieved. This evidence-based guideline for BPH provides recommendations to primary practitioners and urologists for the diagnosis and treatment of BPH in men older than 40 years.

Keywords: Guideline; Lower urinary tract symptoms; Prostate; Prostatic hyperplasia.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Evidence-Based Medicine / methods
  • Humans
  • Lower Urinary Tract Symptoms / etiology
  • Male
  • Prostate-Specific Antigen / blood
  • Prostatectomy / methods
  • Prostatic Hyperplasia / complications
  • Prostatic Hyperplasia / diagnosis*
  • Prostatic Hyperplasia / physiopathology
  • Prostatic Hyperplasia / therapy*
  • Republic of Korea
  • Urodynamics
  • Watchful Waiting

Substances

  • Prostate-Specific Antigen